Take part in a paid clinical trial

The investigational treatment is being developed as a potential future therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). This is the first step in evaluating the treatment’s safety and how it behaves in the body before testing its effectiveness in patients with these conditions. 

This clinical study is part of a first-in-human trial focused on metabolic health. Researchers are exploring how the body responds to a new investigational capsule, and your participation could help pave the way for future therapies.

Chronic Spontaneous Urticaria (CSU) is a skin condition that causes frequent hives and intense itching, often without a known cause. It affects around 65 million people globally, is more common in women, and can significantly impact quality of life—often leading to anxiety or depression due to the constant discomfort. 

Most people with CSU start treatment with antihistamines, but about 1 in 3 patients don’t get enough relief. For those who don’t respond, doctors may try injectable medications which are often inconvenient for patients, and help some, but not all patients.  

This clinical trial is testing a potential new oral medication, which is designed to block a specific “itch switch” in the body. This switch is found on immune cells and nerves in the skin and is believed to play a key role in triggering hives and inflammation. 

We’re inviting individuals to participate in a pivotal clinical study for a potential treatment for Idiopathic Pulmonary Fibrosis (IPF). This disease causes scarring in the lungs, making it hard to breathe.